GLP-1 Pricing Tightens

Expanded supply solves one problem but increases attention on price, access and reimbursement. As GLP-1 volumes rise, pharmacy benefit managers, employers and government programs push harder for rebates on obesity and diabetes drugs.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.